Kathy Ingebrand started to notice something was off when she found herself being short with her family. She was becoming ...

And though drugs that have some effect on Alzheimer’s disease, dementia’s most common manifestation, have recently been ...

For people with anxiety and depression, these conditions can feel like two sides of the same coin. Researchers are exploring ...

The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...

Bristol Myers Squibb (NYSE:BMY) believes Alzheimer’s is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue.

The firm will use its blood-based tests to explore connections between Alzheimer's disease and neuronal α-synuclein conditions including Parkinson's disease.

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

Dementia is commonly viewed as a condition that affects older adults, but mounting evidence reveals that it is not just a ...

Dartmouth Health is the only health care system on the East Coast to be part of the newly launched Brain Health Navigator ...

Researchers at the University of Kentucky (UK) are part of a groundbreaking clinical trial exploring the use of medical ...

Expanded clinical practice guidelines aim to empower all clinicians, regardless of specialty or practice setting to evaluate ...

Alzheimer’s Society has warned urgent action is needed to address the projected 51 per cent rise in dementia cases across ...